CFDs are a leveraged product and can result in losses that exceed deposits. Please ensure you fully understand how CFDs work and what their risks are, and take care to manage your exposure. CFDs are a leveraged product and can result in losses that exceed deposits. Please ensure you fully understand how CFDs work and what their risks are, and take care to manage your exposure.

Earnings look ahead – Shire, Rolls-Royce, TUI

A look to earnings from companies reporting next week.

London Stock Exchange logo
Source: Bloomberg

Shire (FY earnings 16 February)

Currency movements should provide quite the boon for Shire, with sterling weakness doing much to flatter the bottom line, at least on an adjusted basis. However, integration from recent acquisitions will inevitably increase costs, although revenue growth of 7% is still expected.

The new drug Xildra, used to treat dry eye disease, has had a relatively successful launch, which is expected to result in a confident outlook for the year. Also worth watching out for will be the integration of the Baxalta business, having exceeded expected synergies of $600 million in its first year. Pharma firms have the new administration in the US to worry about, with possible ramifications from potential changes to healthcare provision being a key concern.

Having rallied off the February lows, the shares topped out near £54, and have seen a steady sequence of lower highs and lower lows since September. Big support has been found around £43, while the recent bounce off this level has carried the price back to the 200-day simple moving average (SMA) at £46.73, with the January peak at £49.36 the next area to watch. 

Rolls-Royce (full-year earnings 14 February)

Top of everyone’s concerns for Rolls-Royce will be its US business, and whether the bribery scandal has hit performance there. Expectations are for a (albeit, slight) drop in sales, as sales of new engines have come at the expense of older models. In addition, there may be a hit to earnings as a result of FX hedges post Brexit.

Adjusted earnings are forecast to be 24.3p per share, down 58% from a year earlier, while revenue is expected to decline 1.8% to £13.5 billion. At 25 times forward earnings the shares are not as expensive as in the summer, when they traded at 28 times, but they are well above the five-year average of 17 times.

The shares are still in an uptrend (A) from the January 2016 lows, with a dip at the beginning of 2017 finding buyers. They now need to post a daily close above the descending trendline (B) from the July highs, which would open the way to 790p, the October high. 

TUI (Q1 trading update 14 February)

Sector peer Thomas Cook took a heavy knock this week after a cautious statement, so TUI will be hoping it can avoid similar treatment. The firm is on the cusp of the vital booking season for summer holidays, having said in December trading was in line with expectations. The German unit said recently bookings were significantly above levels seen a year ago, so if the UK arm replicates this the shares may see a rerating. At 12 times forward earnings the valuation looks relatively undemanding, although the risk of further terror attacks is one risk to the share price.

The shares broke the descending trendline off the 2016 high back in December, and then fell back to it and rallied, so it looks like the bulls are in charge now. Faltering momentum may indicate sustained profit taking, but so long as the rising trendline off the June lows (B) holds, then it could prove to be a good buying opportunity when the bounce materialises, with a first target being the 2017 high at £12.

This information has been prepared by IG, a trading name of IG Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.  Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. 

CFDs are a leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your initial deposit, so please ensure that you fully understand the risks involved.

Find articles by writer